Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Horn Discusses Next Steps With Atezolizumab in SCLC

Leora Horn, MD
Published: Monday, Oct 15, 2018



Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer (SCLC).

Data from the IMpower133 study presented at the 19th World Conference on Lung Cancer, and simultaneously published in the New England Journal of Medicine, showed that the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage SCLC. This regimen of atezolizumab plus chemotherapy may become the new frontline standard of care for patients with stage IV disease, Horn says.

Next steps are addressing patients who fail the atezolizumab regimen, explains Horn. Right now, the only option for these patients is topotecan, which has not shown much efficacy. There are other agents like lurbinectedin emerging in this space that might have an impact, though.


Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer (SCLC).

Data from the IMpower133 study presented at the 19th World Conference on Lung Cancer, and simultaneously published in the New England Journal of Medicine, showed that the addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage SCLC. This regimen of atezolizumab plus chemotherapy may become the new frontline standard of care for patients with stage IV disease, Horn says.

Next steps are addressing patients who fail the atezolizumab regimen, explains Horn. Right now, the only option for these patients is topotecan, which has not shown much efficacy. There are other agents like lurbinectedin emerging in this space that might have an impact, though.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x